Jefferies Downgrades Supernus Pharmaceuticals (SUPN) to Hold
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/28/2026
- Wall Street ends higher on revived AI momentum
- Meta's $97.5B AI money grab: why Zuckerberg is racing to raise cash before rivals
- Deutsche Bank’s Reid sees potential final dip this year before Santa rally
- UPS tops estimates as efficiency drive gains momentum
- GM to move stock listing to Nasdaq in November, shares gain
Tweet
Share
E-mailGet Alerts SUPN Hot Sheet
Price: $40.96 --0%
Rating Summary:
9 Buy, 3 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 3 | Down: 9 | New: 6
Rating Summary:
9 Buy, 3 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 3 | Down: 9 | New: 6
Join SI Premium – FREE
Jefferies analyst David Steinberg downgraded Supernus Pharmaceuticals (NASDAQ: SUPN) from Buy to Hold with a price target of $23.00 (from $46.00).
For an analyst ratings summary and ratings history on Supernus Pharmaceuticals click here. For more ratings news on Supernus Pharmaceuticals click here.
Shares of Supernus Pharmaceuticals closed at $29.13 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- UBS Upgrades Sandfire Resources NL (SFR:AU) (SNDFY) to Buy
- Jefferies Downgrades Kosmos Energy (KOS:LN) (KOS) to Hold
- Tata Capital Ltd (TATACAP:IN) PT Lowered to INR370 at Nomura/Instinet
Create E-mail Alert Related Categories
Analyst PT Change, DowngradesRelated Entities
Jefferies & CoSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
